基于CD-MOF的pH/ROS敏感的5-ASA输送系统用于性结肠炎治疗
Yanxue Si1,2, Ruitao Cha2,3, Pai Zhang1,2
1Beijing Key Laboratory of Materials Utilization of Nonmetallic Minerals and Solid Wastes, National Laboratory of Mineral Materials, School of Materials Science and Technology, China University of Geosciences (Beijing), Beijing, 100083, P. R. China.
Advanced healthcare materials
|June 23, 2025
概括
这项研究开发了新的微球 (ASA@CM/SL),以改善性结肠炎 (5-ASA) 的5-aminosalicylic 酸 (5-ASA) 输送. 新配方增强了药物溶解性和结肠向性,显示出具有良好生物安全性的显著治疗效果.
科学领域:
- 材料科学 材料科学 材料科学
- 生物医学工程 生物医学工程
- 药理学 药理学是指药理学的学科.
背景情况:
- 性结肠炎 (UC) 的治疗受限于5 - 氨酸 (5-ASA) 的溶解性差和胃肠道吸收.
- 开发先进的药物输送系统对于提高UC管理中的治疗疗效和患者结果至关重要.
研究的目的:
- 为5-ASA.设计一种基于环氧的新型金属有机框架 (CD-MOF) 载体 (ASA@CM).
- 使用藻酸盐/L-氨酸复合物 (SA-LA) 创建向微球 (ASA@CM/SL),以改善5-ASA向结肠的输送.
- 在UC的小鼠模型中评估ASA@CM/SL的治疗疗效和生物安全性.
主要方法:
- 制造装有5-ASA的CD-MOF (ASA@CM),以提高溶解度.
- 将ASA@CM纳入SA-LA复合体,通过电子喷雾形成微球 (ASA@CM/SL).
- 在体外和体内对抗炎症,抗氧化,治疗作用,细胞毒性和器官毒性在硫酸诱导UC小鼠模型中的体外和体内评估.
主要成果:
- ASA@CM/SL有效地提高了5-ASA的溶解度,并保护它免受上部胃肠道环境的影响.
- 微球证明了对结肠的向输送,显著缓解炎症反应,并恢复UC小鼠的肠道屏障功能.
- ASA@CM/SL表现出极好的治疗效果,细胞毒性和器官毒性较低.
结论:
- 开发的ASA@CM/SL微球代表了增强5-ASA可溶性和针对结肠的有效治疗UC治疗的有前途的战略.
- 这种方法提供了一个潜在的平台,可以提供疏水性药物来治疗UC等肠道疾病.
相关概念视频
01:29Drugs for Treatment of Ulcerative Colitis in IBD
244
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
244
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
278
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
278
01:29Inflammatory Bowel Disease IV: Pharmacological Management
204
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
204
01:24Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
707
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
707
01:21Drugs for Treatment of Constipation-Predominant IBS
353
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
353
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
210
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
210